Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Active Biotech in licensing deal regarding ANYARA
Mandate

Vinge assisted Active Biotech in licensing deal regarding ANYARA

October 27, 2016

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Related

Vinge has advised Skeptiva AB in connection with its financing round

 Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

 Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026

Vinge represents Studsvik AB (publ) in the acquisition of Kärnfull Next AB

 Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.
March 10, 2026